Guardant Health Inc
NASDAQ:GH

Watchlist Manager
Guardant Health Inc Logo
Guardant Health Inc
NASDAQ:GH
Watchlist
Price: 103.21 USD -0.92% Market Closed
Market Cap: 13.3B USD

Guardant Health Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Guardant Health Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Guardant Health Inc
NASDAQ:GH
Revenue
$902.6m
CAGR 3-Years
28%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Quest Diagnostics Inc
NYSE:DGX
Revenue
$10.9B
CAGR 3-Years
2%
CAGR 5-Years
5%
CAGR 10-Years
4%
CVS Health Corp
NYSE:CVS
Revenue
$394.1B
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
10%
Cigna Corp
NYSE:CI
Revenue
$268.1B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
22%
Hims & Hers Health Inc
NYSE:HIMS
Revenue
$1.5B
CAGR 3-Years
76%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Laboratory Corporation of America Holdings
NYSE:LH
Revenue
$13.8B
CAGR 3-Years
11%
CAGR 5-Years
2%
CAGR 10-Years
6%
No Stocks Found

Guardant Health Inc
Glance View

Market Cap
12.9B USD
Industry
Health Care

Guardant Health Inc. emerged from the convergence of innovation and necessity, pioneering a transformative approach to cancer diagnostics. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on the potential of liquid biopsy technology. Unlike traditional biopsies that often require invasive procedures, Guardant Health's tests analyze circulating tumor DNA (ctDNA) from a simple blood draw. This standout technology not only provides critical insights into the genomic profile of tumors but also facilitates early cancer detection, treatment monitoring, and recurrence detection, breaking new grounds in precision oncology. The company's flagship product, Guardant360, plays a pivotal role for oncologists by enabling tailored treatment plans based on real-time, dynamic insights into the cancer's genetic mutations. Earning its revenue primarily through partnerships with healthcare providers, pharmaceutical companies, and research institutions, Guardant Health has positioned itself strategically in the medical diagnostics landscape. By offering tests that can be repeatedly adapted to monitor the evolution of cancer over time, the company garners significant interest as it aids in the development of targeted cancer therapies. Pharmaceutical companies, in particular, collaborate with Guardant Health to utilize its technology in clinical trials to identify suitable candidates and assess treatment efficacy. The company's growing influence is further bolstered by its commitment to expanding applications for early cancer detection, laying the groundwork for potential shifts in cancer care paradigms. Thus, Guardant Health, through its innovative fusions of technology and healthcare, forges ahead in transforming cancer management and diagnostics, turning its story into a testament of modern medical advancement.

GH Intrinsic Value
50.09 USD
Overvaluation 51%
Intrinsic Value
Price

See Also

What is Guardant Health Inc's Revenue?
Revenue
902.6m USD

Based on the financial report for Sep 30, 2025, Guardant Health Inc's Revenue amounts to 902.6m USD.

What is Guardant Health Inc's Revenue growth rate?
Revenue CAGR 5Y
27%

Over the last year, the Revenue growth was 30%. The average annual Revenue growth rates for Guardant Health Inc have been 28% over the past three years , 27% over the past five years .

Back to Top